AXSOME THERAPEUTICS INC
AXSMNASDAQTrading Snapshot
- Day Range
- $184.62 – $188.70
- 52-Week Range
- $115.31 – $260.19
- Volume
- $1.90B
- Avg Volume
- $2.53B
- Shares Outstanding
- 51.5M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $638M
- Last Q Revenue
- $218M
- P/E Ratio
- —
- P/S Ratio
- 13.3x
- EPS (TTM)
- $-3.76
- Dividend Yield
- —
- Dilution (1yr)
- +4.3%
Why Investors Own AXSM
- ✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AXSOME THERAPEUTICS INC
AXSM
StockOtter · stockotter.spaceAbout AXSOME THERAPEUTICS INC
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics (NASDAQ: AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitatio
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics (NASDAQ: AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction
Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation,
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM
Bank of America Corp DE bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 452
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.